B
13.40
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bicara Therapeutics Inc. | Bearish | - |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.26% |
| % Held by Institutions | 86.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 31 Dec 2024 | 3,170,509 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (HC Wainwright & Co., 235.82%) | Buy |
| Median | 31.00 (131.34%) | |
| Low | 13.01 (Cantor Fitzgerald, -2.91%) | Buy |
| Average | 29.67 (121.42%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 12.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 13 Mar 2025 | 13.01 (-2.91%) | Buy | 13.35 |
| Wedbush | 12 Feb 2025 | 31.00 (131.34%) | Buy | 13.22 |
| 06 Feb 2025 | 31.00 (131.34%) | Buy | 12.60 | |
| HC Wainwright & Co. | 27 Jan 2025 | 45.00 (235.82%) | Buy | 11.65 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Mar 2025 | Announcement | Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 25 Mar 2025 | Announcement | Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |